{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"37","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"To determine the relative percentage of the ALK fusion within the cohort's gene pool","dispersionType":"Full Range","groups":[{"description":"Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)","id":"OG000","title":"ALK-positive NSCLC With Progression"}],"paramType":"MEDIAN","populationDescription":"Patients with detected ALK fusion","reportingStatus":"POSTED","timeFrame":"32 months","title":"ALK Fusion Allelic Frequency","type":"PRIMARY","unitOfMeasure":"percentage of the ALK fusion"}